Status:
COMPLETED
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
Lead Sponsor:
Eli Lilly and Company
Conditions:
Total Knee Replacement
Total Hip Replacement
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
LY517717 (a capsule given by mouth) is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs. Leg and lung blood clots occ...
Eligibility Criteria
Inclusion
- Are scheduled for total knee or hip replacement surgery (only one side, first time joint replacement)
- Are at least 18 years of age and no more than 75 years of age.
- Have a body weight more than 50 kg and less than 120 kg.
- Sign an approved Eli Lilly and Company informed consent document.
Exclusion
- Have had hip or knee replacement surgery in the non-surgical leg or any surgical procedure in the surgical leg within 6 months prior to enrollment.
- Other surgeries (brain, spinal cord, eye within 12 months; chest or abdominal surgery within 1 month).
- Have taken drugs that might increase possibility of bleeding.
- Other risk factors for bleeding (bleeding disorders, abnormal results on blood tests, ulcers)
- Increased risk for blood clots.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
511 Patients enrolled
Trial Details
Trial ID
NCT00074828
Start Date
December 1 2003
End Date
May 1 2005
Last Update
March 31 2008
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Nedlands, Western Australia, Australia
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Vienna, Austria
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Brussels, Belgium
4
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
Ostrava-Poruba, Czechia